Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Clinical trial NCT05963217 · RECRUITING
Trial details
- NCT number
- NCT05963217
- Sponsor
- University Health Network, Toronto
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-26
- Primary completion
- 2028-06-30
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.